Logo

Biocept: Quyen Dao-Haddock

Nov 18, 2022

Biocept has appointed Quyen Dao-Haddock to its board of directors, effective immediately. The company's board has increased to eight members as a result. Dao-Haddock will serve on Biocept's audit committee. She is a certified public accountant with more than 20 years of accounting experience and is controller of real estate investment trust IQHQ, which is focused on the life sciences industry. She previously was chief accounting officer of Presidio Property Trust. Before that she was corporate controller of American Assets Trust.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.